1. Volume 15, Issue 3, Pages 267-274 (March 2014)
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) 
Prof Fabrice André, MD, Thomas Bachelot, MD, Frederic Commo, MSc, Prof Mario Campone, MD, Monica Arnedos, MD, Véronique Dieras, MD, Magali Lacroix-Triki, MD, Ludovic Lacroix, PharmPhD, Pascale Cohen, PhD, David Gentien, MSc, Jose Adélaide, PhD, Florence Dalenc, MD, Anthony Goncalves, MD, Christelle Levy, MD, Prof Jean-Marc Ferrero, MD, Prof Jacques Bonneterre, MD, Claudia Lefeuvre, MD, Marta Jimenez, MSc, Thomas Filleron, PhD, Prof Hervé Bonnefoi, MD 
The Lancet Oncology 
Volume 15, Issue 3, Pages (March 2014)
DOI: /S (13)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
CGH=comparative genomic hybridisation. *Procedure done twice in 29 patients.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Distribution of targetable genomic alterations among screened patients
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3 Genomic alteration and matched targeted therapies
Efficacy is expressed as the number of responses, defined as objective response or stable disease for >16 weeks.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions